PCSK9 Inhibitor Improves Outcomes for Patients with Peripheral Artery Disease
LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial.
Source: BWH for Journalists - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Peripheral Vascular Disease (PVD) | Research